GO
Loading...

Enter multiple symbols separated by commas

Express Scripts Holding Co

More

  • Early movers: TIF, KORS, TOL, BWS, HRL & more Wednesday, 27 May 2015 | 8:31 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • *Deal values Omnicare at $12.7 bln, including $2.3 bln debt. May 21- CVS Health Corp, the second-largest U.S. drugstore operator, said on Thursday it will buy pharmacy services provider Omnicare Inc for $10.1 billion to expand in the growing market serving the senior patient population. CVS offered $98 per Omnicare share, representing a premium of 4 percent to...

  • 500,000 Americans spend $50K on medicine each year Wednesday, 13 May 2015 | 12:01 AM ET
    Prescription drugs

    More than half a million Americans have annual prescription drug costs of more than $50,000.

  • May 13- More than a half-million U.S. patients had medication costs in excess of $50,000 in 2014, an increase of 63 percent from the prior year, as doctors prescribed more expensive specialty drugs for diseases such as cancer and hepatitis C, according to an Express Scripts report released on Wednesday. The total cost to health plans for U.S. patients with...

  • Spending on this type of meds hit a new milestone Tuesday, 5 May 2015 | 12:01 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.

  • NEW YORK, May 1- U.S. authorities said on Friday that a unit of Express Scripts Holding Co will pay $60 million to resolve claims that it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. Specialty pharmacy Accredo Health Group Inc has agreed to pay $45.1 million to the federal government...

  • NEW YORK, May 1- A unit of pharmacy benefits manager Express Scripts Holding Co will pay $45 million to resolve U.S. claims it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements. The settlement with specialty pharmacy Accredo Health Group Inc was disclosed in court papers filed Thursday in...

  • April 30- Pharmacy service provider Omnicare Inc is getting buyout interest from potential buyers, including Express Scripts Holding Co and CVS Health Corp, Bloomberg reported, citing people with knowledge of the matter. Omnicare is working with Bank of America Corp and Centerview Partners to explore options including a sale, the report said.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • NEW YORK, March 30- UnitedHealth Group Inc's planned takeover of No. 4 U.S. pharmacy benefits provider Catamaran Corp will give the companies added heft in price talks with drug companies, serving as a catalyst for deals allowing other insurers to bulk up. The $12.8 billion deal comes at a time when Wall Street has been parsing the possibilities that top insurers...

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...